AstraZeneca's Top 10 Medicines by Sales in Q2 '24

AstraZeneca reported quarterly earnings a few days back, demonstrating continued strong growth, especially in oncology. Here’s a more detailed look at some of the highlights:

August 12, 2024

Sanofi Revenue by Category - Q2 '24 Earnings Recap

Sanofi announced Q2 results recently, including continued strong growth from Dupixent, along with several new launches and pipeline updates. Here's a deeper dive:

August 12, 2024

BMS Top 10 Medicines by Sales in Q2 '24

Bristol Myers Squibb (BMS) reported its second-quarter earnings last week, showcasing strong growth in its newer medicines portfolio and better-than-expected results for its mature medicines. Here is a closer look at BMS's performance for the quarter:

August 02, 2024

Top 10 BioPharma Companies by Revenue (2003 to 2023)

Over the past 20 years, the top 10 Biopharma companies have almost doubled revenue. Yet, there has been considerable variance among companies. Here's a closer look behind some of the most notable changes.

August 01, 2024

Top 20 Companies by Market Cap (2003 vs. 2024)

In 2003, BioPharma accounted for nearly a quarter of the market cap within the world’s 20 most valuable companies. Today, BioPharma makes up only 5% of the top 20. Here are some driving causes of this change.

August 01, 2024

AbbVie Q2 Earnings: Immunology Strength Overshadows Aesthetics Challenges

Immunology Strength Overshadows Aesthetics Challenges AbbVie reported strong Q2 earnings, driven by immunology drugs Skyrizi and Rinvoq. The company raised guidance for both, with Skyrizi now expected to hit 11B in global sales and Rinvoq 5.7B. Skyrizi and Rinvoq have a combined 40% share of the US Crohn's market. However, aesthetics remained a weak spot with flat sales, as Juvéderm declined due to economic headwinds.

July 29, 2024

The Shifting Spending Priorities of Big Pharma

Explore the shifting spending priorities of big pharma over the past 30 years, including the steep decline in sales & marketing costs and surge in R&D expenditures to develop new drugs.

July 26, 2024

The Prize of the Eyes: Eylea & Vabysmo in Opthalmology

Roche held an Ophthalmology-focused investor event today at the end of the annual American Society of Retina Specialists Meeting in Stockholm, and provided some interesting insights on Vabysmo’s performance vs. Eylea:

July 23, 2024

J&J's Q2 Earnings and Key Milestones in Immunology and Oncology

Johnson & Johnson (J&J) recently reported its Q2 earnings, providing insights into the performance of its core divisions, Innovative Medicines and MedTech, following the spin-off of its consumer arm, Kenvue.

July 22, 2024

Small Molecule GLP-1 Overview

Two key GLP-1 updates came out in the last week, both on small molecules: Pfizer's update on danuglipron, and Roche's topline results yesterday on CT-996, which caused shares of competitors to drop sharply - here's the recap:

July 18, 2024